US Patent 7,612,102: Nicardipine Hydrochloride Premixed Injection Patent Scope and Landscape
US Patent 7,612,102 protects selected ready-to-use nicardipine hydrochloride parenteral solutions, particularly formulations in dextrose or sodium chloride packaged in nonpolar polymer containers. The claims combine composition ranges, pH control, container compatibility, and stability performance. The patent does not broadly cover nicardipine hydrochloride, all injectable nicardipine products, or every premixed formulation.
The strongest commercial coverage is directed to a ready-to-administer product containing approximately 0.1-0.2 mg/mL nicardipine hydrochloride in dextrose or sodium chloride, adjusted to pH 3.6-4.7, and packaged in copolyester, polyethylene, or polyolefin. Claims 7-11 are particularly important because claim 7 omits the one-year and three-month stability limitations found in related claims.
What patent protects premixed nicardipine hydrochloride injection?
US 7,612,102 protects a pharmaceutical composition rather than a method of treating hypertension or a manufacturing process. Its central technical subject is a stable, premixed aqueous nicardipine hydrochloride solution for parenteral administration.
Core claim elements
A product generally must satisfy the following limitations to fall within the principal claim set:
| Element |
Claimed requirement |
| Active ingredient |
Nicardipine hydrochloride |
| Administration |
Parenteral |
| Dosage form |
Premixed aqueous solution |
| pH |
About 3.6 to about 4.7 |
| Nicardipine concentration |
0.1-0.4 mg/mL in claim 1; 0.1-0.2 mg/mL in claims 5-7 |
| Tonicity agent |
Dextrose or sodium chloride |
| Dextrose range |
About 4.5%-5%, or 46-50 mg/mL |
| Sodium chloride range |
About 0.8%-0.9%, or 8.3-9 mg/mL |
| Buffer |
Amount sufficient to maintain the claimed pH |
| Container |
Pharmaceutically acceptable container; specified polymers in claims 4-7 |
| Stability |
Depending on claim, less than 10% concentration loss and/or less than about 3% total impurities |
| Optional excipients |
Sorbitol, hydrochloric acid, sodium hydroxide, or both |
The claims are cumulative. A product must satisfy every limitation of the asserted claim, either literally or under the doctrine of equivalents where legally available.
How broad are the independent claims in US 7,612,102?
Claims 1, 5, 6, and 7 are the independent composition claims. Their practical scope differs materially.
Claim 1
Claim 1 covers a premixed aqueous solution containing:
- 0.1-0.4 mg/mL nicardipine hydrochloride;
- either 4.5%-5% dextrose or 0.8%-0.9% sodium chloride;
- a buffer maintaining pH at 3.6-4.7;
- a container that prevents contact with polar polymers;
- less than 10% nicardipine loss after at least one year at room temperature; and
- less than about 3% total impurity formation.
Claim 1 is broader than claims 5-7 in nicardipine concentration. It is narrower in its container-language requirement because the solution must not come into contact with polar polymers. It also carries both long-term stability limitations.
The phrase “such that the solution does not come into contact with polar polymers” is significant. It focuses on material compatibility and extractables or adsorption-related stability, rather than merely requiring a particular named container material.
Claim 5
Claim 5 narrows the nicardipine concentration to 0.1-0.2 mg/mL and expressly requires a container comprising copolyester, polyethylene, or polyolefin. It retains both one-year stability requirements.
Because claim 5 expressly identifies the container polymer classes, a product using glass, polypropylene, or another material would require a separate infringement analysis. The claim does not recite sorbitol, so the presence of sorbitol does not by itself avoid claim 5.
Claim 6
Claim 6 covers the 0.1-0.2 mg/mL formulation with dextrose or sodium chloride, a buffer, and 0-4 mg/mL sorbitol. It also requires the named polymer container classes and both one-year stability outcomes.
The “0 mg/mL to about 4 mg/mL” range is unusual in scope. It expressly includes formulations with no sorbitol. As a result, the sorbitol limitation does not materially distinguish a formulation lacking sorbitol from one containing a low amount of sorbitol, provided the other elements are met.
Claim 7
Claim 7 is the most commercially important independent claim. It covers the same basic formulation as claim 6 but does not include the one-year concentration-loss or impurity limitations.
Claim 7 requires:
- 0.1-0.2 mg/mL nicardipine hydrochloride;
- 46-50 mg/mL dextrose or 8.3-9 mg/mL sodium chloride;
- 0-4 mg/mL sorbitol;
- buffer-controlled pH of 3.6-4.7; and
- a copolyester, polyethylene, or polyolefin container.
A competing product may meet claim 7 even if it has not been demonstrated to satisfy the one-year stability thresholds. Claims 8-11 add specific three-month and one-year performance limitations to claim 7.
What formulations are protected by the dependent claims?
| Claim |
Added limitation |
Commercial significance |
| 2 |
Hydrochloric acid, sodium hydroxide, or both as pH adjuster |
Captures common pH-adjustment systems |
| 3 |
1-4 mg/mL sorbitol |
Narrows claim 1 to a specified sorbitol range |
| 4 |
Container comprises copolyester, polyethylene, or polyolefin |
Identifies preferred polymer packaging |
| 8 |
Less than 10% concentration loss after three months |
Adds intermediate stability requirement |
| 9 |
Less than about 3% total impurities after three months |
Adds intermediate impurity limit |
| 10 |
Less than 10% concentration loss after one year |
Adds long-term assay stability |
| 11 |
Less than about 3% total impurities after one year |
Adds long-term impurity stability |
| 12-15 |
Citric acid buffer |
Narrows the buffer to citric acid |
Claims 12-15 are formulation-specific claims directed to citric acid. A product using citrate, phosphate, acetate, or another buffer may avoid those dependent claims while still implicating an applicable independent claim.
When does US Patent 7,612,102 lose exclusivity?
The patent issued on November 3, 2009. Its effective patent term is governed by 35 U.S.C. § 154 and generally runs 20 years from the earliest effective nonprovisional filing date, subject to patent-term adjustment and any applicable patent-term extension.
Public patent records identify a nominal term endpoint in the 2025 period for this patent family. The operative date depends on the earliest effective nonprovisional filing and any recorded patent-term adjustment. FDA regulatory exclusivity is separate from patent term and does not extend the patent.
A patent expiration date also does not eliminate potential exposure under other patents covering:
- nicardipine injection compositions;
- container systems;
- manufacturing or filling methods;
- specific impurity-control methods;
- delivery devices; or
- later improvements.
What is the Orange Book status of nicardipine injection?
The Orange Book analysis must distinguish the branded Cardene IV product, generic nicardipine hydrochloride injections, and ready-to-use premixed presentations. Orange Book listings can identify patents submitted by an NDA holder, but the absence of a listing does not establish freedom to operate.
US 7,612,102 is directed to a formulation and container configuration associated with premixed nicardipine hydrochloride injection. Its commercial relevance is therefore greater for ready-to-use bags or containers than for concentrated nicardipine products requiring dilution before administration.
The principal regulatory distinction is:
| Product type |
Relevance of US 7,612,102 |
| Nicardipine concentrate for dilution |
Lower, unless the final marketed product meets the claimed composition and container limitations |
| Premixed nicardipine in 5% dextrose |
High potential relevance |
| Premixed nicardipine in 0.9% sodium chloride |
High potential relevance |
| Glass ampule or vial |
Less likely to meet the polymer-specific claims, but claim 1 requires separate analysis |
| Polyolefin or polyethylene bag |
Directly aligned with claims 4-7 |
| Formulation outside pH 3.6-4.7 |
Potentially outside the literal scope |
| Concentration outside the claimed ranges |
Potentially outside the literal scope, subject to equivalents analysis |
FDA approval of a generic product does not itself resolve patent infringement. Under the Hatch-Waxman framework, an abbreviated new drug application may involve a Paragraph IV certification against listed patents, a Paragraph III certification, or a statement that the patent is not relevant to the proposed product.
Which companies are challenging nicardipine patent rights?
The supplied claim information does not establish a particular Paragraph IV challenger, ANDA number, district-court case, or settlement agreement. Patent litigation and ANDA certifications must be evaluated against current FDA records, Orange Book entries, USPTO assignment data, and PACER litigation records.
A generic manufacturer faces the highest product-specific risk when its proposed product matches all of the following:
- 0.1-0.2 mg/mL nicardipine hydrochloride;
- 5% dextrose or 0.9% sodium chloride;
- pH 3.6-4.7;
- sorbitol at 0-4 mg/mL or an equivalent excipient profile; and
- a copolyester, polyethylene, or polyolefin container.
A formulation design-around may target one or more claim elements, including concentration, pH, tonicity agent, buffer, polymer, or stability profile. The commercial value of a design-around depends on whether the alternative remains pharmaceutically acceptable, stable, compatible with IV administration, and suitable for FDA approval.
How strong is the patent estate for nicardipine premix products?
US 7,612,102 has meaningful product-level scope but limited subject-matter breadth. Its strength comes from the combination of formulation and packaging limitations.
Strengths
- It covers both dextrose and sodium chloride tonicity systems.
- Claims 5-7 align with conventional ready-to-use concentrations.
- Claim 7 lacks explicit long-term stability testing limitations.
- The patent links polymer selection to product stability.
- Dependent claims separately protect sorbitol, citric acid, pH adjustment, and stability performance.
Limitations
- The claims do not cover nicardipine hydrochloride as an active ingredient generally.
- They do not cover every injectable concentration.
- They do not broadly cover all buffers.
- Claims 5-7 require specified polymer classes.
- Claims 1 and 5-6 include demanding one-year stability limitations.
- The claims are composition claims and do not independently block every manufacturing route.
The strongest invalidity pressure would likely focus on anticipation or obviousness based on prior disclosures combining nicardipine concentration, isotonic vehicle, acidic pH, buffer, and compatible packaging. The patent’s stability data may support nonobviousness, but the enforceability analysis would depend on the complete specification, prosecution history, cited references, written-description support, enablement, and any terminal disclaimer.
What patent litigation and settlement issues affect generic launch?
A generic launch analysis should separate four events:
| Event |
Business effect |
| Paragraph IV notice |
May trigger patent litigation and a 30-month FDA approval stay under applicable conditions |
| District-court filing |
Determines whether the patent is actively being enforced against the ANDA |
| Settlement agreement |
May establish a licensed or agreed launch date |
| Patent expiration |
Removes infringement risk under that patent, subject to other rights |
A settlement may include an authorized generic arrangement, supply agreement, launch license, or no-admission clause. No settlement terms should be inferred solely from the existence of an approved generic nicardipine product.
What manufacturing and IP barriers remain after patent expiration?
Patent expiry does not remove the technical barriers inherent in the claims. A manufacturer still must demonstrate:
- assay stability;
- impurity control;
- container compatibility;
- extractables and leachables compliance;
- sterility assurance;
- particulate control;
- pH and osmolality consistency;
- bag or container integrity; and
- FDA-compliant commercial-scale filling.
The patent’s focus on nonpolar polymers indicates that container selection is part of the product’s stability strategy. A manufacturer using a different polymer may avoid literal claim coverage but incur new compatibility and regulatory-development costs.
How does US 7,612,102 compare with ordinary nicardipine injection patents?
| Issue |
US 7,612,102 |
Conventional API or treatment patent |
| Primary subject |
Premixed formulation and container |
Active ingredient, treatment method, or synthesis |
| Key limitation |
Concentration, pH, tonicity, polymer, stability |
Chemical structure, dosage, disease, or process |
| Product risk |
Highest for ready-to-use IV bags |
Depends on molecule or therapeutic indication |
| Design-around route |
Change concentration, vehicle, pH, buffer, or container |
Change molecule, method, or process |
| Regulatory relevance |
CMC and product presentation |
Clinical indication or drug substance |
Key Takeaways
- US 7,612,102 is a formulation and packaging patent for stable, premixed nicardipine hydrochloride injection.
- Claims 5-7 target approximately 0.1-0.2 mg/mL nicardipine in dextrose or sodium chloride.
- Copolyester, polyethylene, and polyolefin containers are central to the narrower claims.
- Claim 7 is the broadest commercially relevant independent claim because it omits explicit long-term stability results.
- Claims 8-11 add three-month and one-year stability requirements.
- Claims 12-15 specifically protect citric acid-buffered embodiments.
- The patent does not broadly cover all nicardipine injections or all nicardipine treatment methods.
- The nominal patent term falls in the 2025 period, subject to the recorded patent-term adjustment and effective filing date.
- Patent expiry does not eliminate regulatory, manufacturing, container-compatibility, or other patent-estate risks.
- A final freedom-to-operate opinion requires comparison of the proposed product against each limitation and review of the patent’s prosecution and assignment records.
FAQs About US Patent 7,612,102
Does US 7,612,102 cover nicardipine concentrate?
Not automatically. The claims focus on a premixed aqueous solution. A concentrate that requires dilution may fall outside the claims unless its marketed composition and container satisfy the required limitations.
Does a 0.2 mg/mL nicardipine product automatically infringe?
No. Concentration alone is insufficient. The product must also be evaluated for pH, tonicity agent, buffer, sorbitol, container material, premixed presentation, and any applicable stability limitations.
Can a manufacturer avoid the patent by using glass?
Glass may avoid the polymer-specific limitations in claims 4-7, but claim 1 uses broader container language and separately requires that the solution not contact polar polymers. Other claims and patents may also apply.
Is citric acid required for infringement?
No. Citric acid is required only under claims 12-15. The independent claims require a buffer but do not limit the buffer to citric acid.
Does FDA approval prove that a generic product does not infringe US 7,612,102?
No. FDA approval addresses safety, efficacy, quality, and regulatory requirements. Patent infringement is a separate legal issue determined by the asserted claims, product facts, patent status, and applicable litigation or settlement rights.
References
- United States Patent and Trademark Office. (2009). U.S. Patent No. 7,612,102, stable formulations of nicardipine hydrochloride.
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations.
- U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations.
- U.S. Code, 35 U.S.C. § 154. Patent term.
- U.S. Code, 21 U.S.C. § 355. New drugs and abbreviated applications.
- U.S. Patent and Trademark Office. (n.d.). Manual of Patent Examining Procedure.
